Cyclopamine

For research use only.

Catalog No.S1146 Synonyms: 11-deoxojervine

49 publications

Cyclopamine Chemical Structure

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cyclopamine has been cited by 49 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine (11-deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NEHUbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLZU4pJUUN3ME21Mlg3PjZizszN Mn3IV2FPT0WU
DOHH-2 NHfqeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDDTWM2OD17LkO1Olg6KM7:TR?= M{nlSHNCVkeHUh?=
no-10 M1TzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO2SGo{UUN3ME25MlkxOzlizszN MojIV2FPT0WU
LS-513 NVLXdGFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHRVW5KSzVyPUGxMlM2PDdizszN NILaV4ZUSU6JRWK=
ALL-PO NF6xR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPodJBCUUN3ME2xNU44PzN2IN88US=> Mn\zV2FPT0WU
8-MG-BA MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3xPFRKSzVyPUGzMlEyOjNizszN MX\TRW5ITVJ?
RPMI-8402 NHnZ[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\iS2lEPTB;MUWuPFU{PyEQvF2= MnjlV2FPT0WU
EoL-1-cell MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV34NGtoUUN3ME2xPE42QTR6IN88US=> MUTTRW5ITVJ?
NALM-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF7LkCxOlch|ryP NW[2XG5yW0GQR1XS
DEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHyNlM5UUN3ME2yNE4yPDdzIN88US=> MW\TRW5ITVJ?
SR NGfZOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHHRYhKSzVyPUKzMlY4OTVizszN NWPDfWpLW0GQR1XS
697 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHNTWM2OD1{Nj62NVU2KM7:TR?= M1HYfnNCVkeHUh?=
COLO-829 NI\6U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ4Lki0PFMh|ryP MmO4V2FPT0WU
EVSA-T NXL6cGJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PUNGlEPTB;MkeuOVU3OSEQvF2= MYXTRW5ITVJ?
ATN-1 M1\PNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTNzLkKzNlkh|ryP MnP6V2FPT0WU
L-363 NV3Rb5JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTNzLke0OlEh|ryP MYXTRW5ITVJ?
LAMA-84 NGDZWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7GTWM2OD1|Mj61NlEyKM7:TR?= NXqwVYFIW0GQR1XS
NOS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PldGlEPTB;M{SuNlk2PiEQvF2= NGLnN|NUSU6JRWK=
BB30-HNC M3vHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHJfpVKSzVyPUO0MlM{ODZizszN MnHtV2FPT0WU
BC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO1O3BKSzVyPUO3Mlk4PDZizszN NYnYPW41W0GQR1XS
IST-SL2 M3u2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDpdpNKSzVyPUO4MlIzPCEQvF2= NYnsVopJW0GQR1XS
D-392MG NWnuS2FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTRyLkKyNVUh|ryP NHi4N3JUSU6JRWK=
no-11 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnOTnpKSzVyPUSwMlU2OjFizszN MlzVV2FPT0WU
LC4-1 NGDmRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRyLki3NVYh|ryP MlLWV2FPT0WU
A388 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID3O|lKSzVyPUSyMlU5PDhizszN MVjTRW5ITVJ?
NTERA-S-cl-D1 NV7IfWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37ZU2lEPTB;NEKuO|A4PCEQvF2= MWPTRW5ITVJ?
CESS Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\uTWM2OD12ND6yNlMzKM7:TR?= MkDRV2FPT0WU
RS4-11 NHP5fXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuzTWM2OD12OT6wPVM5KM7:TR?= NW\qPI02W0GQR1XS
MS-1 NE[1SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTHSItJUUN3ME21NE46OzVzIN88US=> MW\TRW5ITVJ?
CTV-1 M{TjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTVzLkC3OEDPxE1? MYrTRW5ITVJ?
D-502MG M4jZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnZUZRKSzVyPUWxMlYzPzFizszN MVLTRW5ITVJ?
ML-2 NUfZUo5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO2SFFKSzVyPUWyMlkyQTVizszN Mm\vV2FPT0WU
SK-NEP-1 NFWxVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPDTWM2OD13Mz6zPVI{KM7:TR?= MWfTRW5ITVJ?
LOXIMVI M3jRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPuTVhCUUN3ME21N{42QDh2IN88US=> MmW1V2FPT0WU
DJM-1 M{Hwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTV4LkOzPVEh|ryP M3TITHNCVkeHUh?=
GI-1 NVTHVWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e2cGlEPTB;NU[uOlE1QSEQvF2= NX62d5ZHW0GQR1XS
IST-MES1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnMUpRKSzVyPU[wMlU1QTNizszN NIrTemRUSU6JRWK=
MV-4-11 NIO5N4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\oVnNKSzVyPU[wMlY2OzhizszN MUnTRW5ITVJ?
OVCAR-4 NX7zRYhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\aWYlKSzVyPU[zMlU3PTdizszN NWSxO5Z3W0GQR1XS
KE-37 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rVd2lEPTB;Nk[uNlY3QCEQvF2= M4rmdnNCVkeHUh?=
D-542MG M{Tje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:4ZnRKSzVyPU[4MlQyOzVizszN MXLTRW5ITVJ?
MHH-PREB-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\lR2lEPTB;N{KuPFQ1OSEQvF2= NHj3S|BUSU6JRWK=
MRK-nu-1 NX;XOm5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fWWmlEPTB;N{OuOFcxPSEQvF2= M4rGdnNCVkeHUh?=
D-247MG MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfMZZNKSzVyPUezMlU1PDJizszN M33nVXNCVkeHUh?=
OCI-AML2 NUTYVWhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH5TWM2OD15Nj65N|Y6KM7:TR?= NUT6RngxW0GQR1XS
LP-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm1TWM2OD16Mj64O|MyKM7:TR?= M1vVVHNCVkeHUh?=
HCC1599 NUX3V|NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jCSGlEPTB;OESuNlg{PyEQvF2= NVmxW24{W0GQR1XS
KARPAS-45 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO4TWM2OD16ND62PVkzKM7:TR?= MkDUV2FPT0WU
BE-13 NGXERolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTl7LkC0O|ch|ryP NWHOUm1CW0GQR1XS
GCIY NXHW[FlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzrTWM2OD17OT6wPVU1KM7:TR?= NEPtSVZUSU6JRWK=
BV-173 M2qxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\ZN2lEPTB;MUCwMlMzPSEQvF2= NUfrT|ZNW0GQR1XS
LB2518-MEL NWLNZlk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrkTnRKSzVyPUGwNE44QDlizszN MUfTRW5ITVJ?
KS-1 NWfuNWlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PPWmlEPTB;MUCxMlY{QSEQvF2= M{\OOHNCVkeHUh?=
MOLT-16 NHvrc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTNOHBXUUN3ME2xNFQvQTh4IN88US=> M1vWVXNCVkeHUh?=
NCI-H1770 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFyOD63PFQh|ryP NV6x[4N4W0GQR1XS
NCI-H82 NEPrdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL3fZpPUUN3ME2xNVAvQTd4IN88US=> NX\YNm9oW0GQR1XS
NCCIT M4LUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFzMj61Nlkh|ryP NY\BV4JuW0GQR1XS
KALS-1 NUP6TXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nvcGlEPTB;MUG1Mlk1OSEQvF2= NWiybG05W0GQR1XS
LB2241-RCC NV\z[XJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v5fWlEPTB;MUG2MlY4QSEQvF2= MYXTRW5ITVJ?
HH MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFzNz6zPVUh|ryP MUPTRW5ITVJ?
HD-MY-Z MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PuXWlEPTB;MUG4MlQ5QCEQvF2= Mke5V2FPT0WU
EB-3 M2\aTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzIfnJbUUN3ME2xNlMvODl2IN88US=> NHLBe|VUSU6JRWK=
BL-70 NEf2S2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjxVW1qUUN3ME2xNlMvOTJ5IN88US=> NWLqTHQ3W0GQR1XS
K-562 M1rW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPhTWM2OD1zMk[uNlQ2KM7:TR?= M1n0NXNCVkeHUh?=
HT-144 MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7nUY02UUN3ME2xN|MvOTZ2IN88US=> MonzV2FPT0WU
PF-382 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF|ND6zOlEh|ryP M{L6UXNCVkeHUh?=
RPMI-8226 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF|NT6wOFUh|ryP NWXBWFRtW0GQR1XS
NCI-H1355 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3INopKSzVyPUGzOU42QDdizszN NXXMeYdPW0GQR1XS
LXF-289 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluyTWM2OD1zM{muO|gyKM7:TR?= NIHHOY1USU6JRWK=
NCI-H69 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF2Mj65N|Ih|ryP NH\VeZFUSU6JRWK=
SK-MEL-1 Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[3TWM2OD1zNEeuNVMh|ryP NH3DW5ZUSU6JRWK=
KARPAS-299 NXHsWFBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm2d5VqUUN3ME2xOFkvOTJizszN M2HiOHNCVkeHUh?=
GB-1 NX;NeJVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnlTWJKSzVyPUG0PU4{OjJizszN NGXKN5JUSU6JRWK=
CMK MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDrTWM2OD1zNEmuOVE2KM7:TR?= NF61dFlUSU6JRWK=
MPP-89 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DsTGlEPTB;MUW2MlA{PSEQvF2= MYjTRW5ITVJ?
KU812 NV74e25WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGqzOnNKSzVyPUG2NU46ODJizszN MljqV2FPT0WU
REH M{XYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL5[m1KSzVyPUG2Nk4yOjVizszN MkfvV2FPT0WU
NEC8 NWTRWodwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF4NT6wNlYh|ryP MkPHV2FPT0WU
KP-N-YS MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF4OD6zPVUh|ryP MmLTV2FPT0WU
Ramos-2G6-4C10 M1PvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF4OT65NVUh|ryP MX;TRW5ITVJ?
Becker MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTieHZKSzVyPUG3OE4yQCEQvF2= M{TydXNCVkeHUh?=
LB647-SCLC Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP4TWM2OD1zN{WuPFQ2KM7:TR?= NETsfHlUSU6JRWK=
LU-139 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF5OD6wNVkh|ryP MofXV2FPT0WU
QIMR-WIL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnqTWM2OD1zN{muOlQ3KM7:TR?= MXzTRW5ITVJ?
NCI-H1395 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF5OT65PVYh|ryP MkTUV2FPT0WU
NOMO-1 NYDOdW9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPndlBKSzVyPUG4Nk45PSEQvF2= NFHibW5USU6JRWK=
GI-ME-N M4Pm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDxVppKSzVyPUG4O{46PjlizszN MnHGV2FPT0WU
KMS-12-PE NEmyOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LnU2lEPTB;MUi5MlI4OyEQvF2= MXvTRW5ITVJ?
Daudi M2\6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnmzTWM2OD1zOUGuNVI5KM7:TR?= NXjYOJIxW0GQR1XS
LB996-RCC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF7MT62PVkh|ryP NY\oOGtTW0GQR1XS
NCI-H2107 NXnzeGg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojiTWM2OD1zOUOuO|M6KM7:TR?= NVTPT29JW0GQR1XS
SK-PN-DW Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnSe3pKSzVyPUG5OE44OTlizszN NUDocYF[W0GQR1XS
MC-CAR MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjCUolKSzVyPUKwNk4zPTNizszN MVHTRW5ITVJ?
SNB75 NH\WcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXpfFRkUUN3ME2yNlEvQTRizszN NYTxU2YzW0GQR1XS
ES4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFXmlEPTB;MkKzMlc5OyEQvF2= M2jNTnNCVkeHUh?=
KARPAS-422 M{f0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq5emZtUUN3ME2yNlgvOzV{IN88US=> MnjmV2FPT0WU
NCI-H1648 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLiTY1KSzVyPUKyPU41QDlizszN MX\TRW5ITVJ?
ES6 M{Thcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP1SZRKSzVyPUKzPU41OyEQvF2= M4HL[nNCVkeHUh?=
KNS-81-FD Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\QRYFnUUN3ME2yOFEvOTl5IN88US=> NXW4VItnW0GQR1XS
JAR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP6cHJKSzVyPUK1Ok4zOjVizszN M1P6NXNCVkeHUh?=
NB1 NFe3d|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO2WmRKSzVyPUK2NE42OTZizszN M{f1dHNCVkeHUh?=
D-336MG MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnUfoxKSzVyPUK2NE43QThizszN NWf5[29wW0GQR1XS
BC-3 NGK2[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLuWGFKSzVyPUK2OU4yPzhizszN Mmi1V2FPT0WU
HCC2218 NXHidmJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITJToFKSzVyPUK2Ok41OTVizszN M17hcnNCVkeHUh?=
TE-9 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGxSWVKSzVyPUK2Ok43OjdizszN MmXWV2FPT0WU
LB1047-RCC NUTSZ2lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfUTWM2OD1{Nk[uO|U{KM7:TR?= MYXTRW5ITVJ?
CTB-1 NXLEc|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ4OT65O|Mh|ryP NEDjdoVUSU6JRWK=
NB7 NEWzVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37XWmlEPTB;MkexJO69VQ>? MWPTRW5ITVJ?
ST486 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDZTWM2OD1{N{euOFEzKM7:TR?= NECzXoZUSU6JRWK=
HCC1187 NEP5SGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTLNGlKSzVyPUK4Nk45OTFizszN MYLTRW5ITVJ?
NCI-SNU-16 NUXhO2tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPiSG9MUUN3ME2yPFQvOjR6IN88US=> M2nCTXNCVkeHUh?=
COR-L279 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7RfVNKSzVyPUK5NU42QDRizszN MUDTRW5ITVJ?
ES8 MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS1blBqUUN3ME2yPVQvOTh{IN88US=> NVj5eI5RW0GQR1XS
U-698-M Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ7OD6yOFMh|ryP M1\2enNCVkeHUh?=
HEL MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNyOT6xOFkh|ryP NEGxfFFUSU6JRWK=
KINGS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLhXY5UUUN3ME2zNVAvPjd2IN88US=> MnrYV2FPT0WU
KY821 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTN|Nj61PVUh|ryP Mn\CV2FPT0WU
MZ1-PC NFLjc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN2NT62NVgh|ryP M3r1[HNCVkeHUh?=
LS-411N Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13WcWlEPTB;M{W0MlY3KM7:TR?= NGXZT5hUSU6JRWK=
SIG-M5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHGfmJXUUN3ME2zOVkvPzh{IN88US=> NILDbYxUSU6JRWK=
HT MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L2SWlEPTB;M{[3MlcyOSEQvF2= M4\NeHNCVkeHUh?=
HC-1 NHj2RYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLoXFJZUUN3ME2zOlcvPzh5IN88US=> NWDFeHF6W0GQR1XS
NCI-H1694 NFjDUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnaUVh7UUN3ME2zO|IvQTN2IN88US=> NV3EdFFSW0GQR1XS
BB65-RCC M1zMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXTTWM2OD1|N{[uNlQ2KM7:TR?= M1vvb3NCVkeHUh?=
HAL-01 NHPHVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTN5OT64N|gh|ryP MU\TRW5ITVJ?
ARH-77 NFHEUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG2TWM2OD1|OUSuNFA5KM7:TR?= M4DR[HNCVkeHUh?=
MZ7-mel NX\peHF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XZZmlEPTB;M{m3MlI{OyEQvF2= MX;TRW5ITVJ?
SIMA MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRyMz65N|Mh|ryP NHrRR5pUSU6JRWK=
DG-75 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvjTWM2OD12MUWuOlk5KM7:TR?= MkfnV2FPT0WU
HUTU-80 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTRzOT6xPFUh|ryP M17kOnNCVkeHUh?=
KNS-42 M4HM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTR{NT64NVUh|ryP MXLTRW5ITVJ?
SH-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7OTWM2OD12MkeuOVY2KM7:TR?= NFLu[JBUSU6JRWK=
L-540 M361bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTR|MT6wN|Eh|ryP MljCV2FPT0WU
NB10 NIjQPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfqd5o4UUN3ME20OFEvOjN2IN88US=> M2nMRnNCVkeHUh?=
ES1 NX7rbY5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uycGlEPTB;NEWyMlc2OyEQvF2= MoCwV2FPT0WU
KMOE-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTR3Nj63NVEh|ryP MkTJV2FPT0WU
MC116 M{PQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTR3OD6xNVYh|ryP NFTWb4dUSU6JRWK=
RCC10RGB M3q2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7STWM2OD12NkCuNFA2KM7:TR?= M3y5fHNCVkeHUh?=
RL95-2 NVf6fHV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTR4MD6yN|ch|ryP Ml\iV2FPT0WU
Raji M1PsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjIc2lKSzVyPUS2PE4yPDNizszN M4n1c3NCVkeHUh?=
CAS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KzcmlEPTB;NEeyMlA4OyEQvF2= NWrMNZROW0GQR1XS
Calu-6 NYPxNnprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m1VmlEPTB;NEe1MlI3PSEQvF2= MYjTRW5ITVJ?
KG-1 NYXCdZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTR5OD60OEDPxE1? NGnZSIpUSU6JRWK=
LB771-HNC NFT4SlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjQWlk2UUN3ME20PFIvOjN{IN88US=> NFXqU3NUSU6JRWK=
ACN NVnST4pmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHJTWM2OD12OUOuOVk6KM7:TR?= M3u3fnNCVkeHUh?=
KM12 MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR7Nj61PFkh|ryP NXzMfZlLW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
NF-κB / Cyclin D1 / MMP2 / MMP9; 

PubMed: 23599805     


Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9. 

Gli1 / TGF-β1 / CXCR4; 

PubMed: 26137001     


Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h.

Snail / E-cadherin / Slug / Vimentin ; 

PubMed: 26859575     


SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT.

23599805 26137001 26859575
Immunofluorescence
Vimentin; 

PubMed: 24553082     


Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.

PCNA / β-catenin; 

PubMed: 28747625     


Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times.

24553082 28747625
In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
- Collapse

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
- Collapse
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine
Smiles CC1CC2C(C(C3(O2)CCC4C5CC=C6CC(CCC6(C5CC4=C3C)C)O)C)NC1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID